Ponatinib circumvents all types of imatinib resistance in chronic myelogenous leukemia cell lines

Cell Cycle. 2013 Jun 1;12(11):1645-6. doi: 10.4161/cc.24982. Epub 2013 May 10.
No abstract available

Keywords: BCR-ABL; T315I mutation; TKI; chronic myelogenous leukemia; dasatinib; imatinib; nilotinib; ponatinib; resistance.

Publication types

  • Editorial

MeSH terms

  • Apoptosis / drug effects*
  • Benzamides / therapeutic use
  • Benzamides / toxicity*
  • Cell Line, Tumor
  • Drug Resistance, Neoplasm / drug effects*
  • Fusion Proteins, bcr-abl / genetics
  • Fusion Proteins, bcr-abl / metabolism
  • Humans
  • Imatinib Mesylate
  • Imidazoles / therapeutic use
  • Imidazoles / toxicity*
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / metabolism
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Mutation
  • Piperazines / therapeutic use
  • Piperazines / toxicity*
  • Protein Kinase Inhibitors / therapeutic use
  • Protein Kinase Inhibitors / toxicity*
  • Pyridazines / therapeutic use
  • Pyridazines / toxicity*
  • Pyrimidines / therapeutic use
  • Pyrimidines / toxicity*

Substances

  • Benzamides
  • Imidazoles
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyridazines
  • Pyrimidines
  • ponatinib
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl